Real-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study

Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palb...

Descripción completa

Detalles Bibliográficos
Autores principales: Mycock, Katie, Zhan, Lin, Taylor-Stokes, Gavin, Milligan, Gary, Mitra, Debanjali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924325/
https://www.ncbi.nlm.nih.gov/pubmed/33498797
http://dx.doi.org/10.3390/curroncol28010066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924325/
https://www.ncbi.nlm.nih.gov/pubmed/33498797
http://dx.doi.org/10.3390/curroncol28010066

Ejemplares similares